Top picks in English

Danish CROs benefit from life science growth spurt

Though competition on the contract research market is getting fiercer the demand for clinics is also increasing. Three of Denmark's biggest contract research organizations anticipate growth during the next couple of years.

The man to lead Denmark's new life science office

A man with experience in the Danish Business Authority is to lead the Danish government's newly established life science unit. "I am super proud and excited for the job," says the industry's new go to-chief.

Medicines Council refuses dialogue with Biogen

After the second rejection of the muscular atrophy drug Spinraza, Biogen invites the Danish Medicines Council to a dialogue meeting. The aim is to solve the apparently deadlocked conflict but the Medicines Council rejects the proposal. General Manager in Biogen does not understand the decision.

Danish biotech merger to attract major investors

Biotech companies Oncology Venture and Medical Prognosis Institute are planning a merger that will take the companies from the Swedish stock exchanges for growth companies to Stockholm's main market. "Investors and potential partners have expressed their desire for a one-stop-shop and this is what we comply with," says the CEO in both companies.

Saniona turns to rare diseases

Danish Saniona's candidate tesomet is already in phase II against a genetic disease causing obesity. According to CFO Thomas Feldthus, the candidate also has potential in another orphan drug indication.

Pharma giant draws digital inspiration from Copenhagen pupils

Boehringer Ingelheim participates in a project teaching Copenhagen pupils to develop digital solutions to challenges in the business world. "It is not unlikely that we carry on with one or more of the ideas," says the Danish Market Access Director.

Sanofi defeats Novo Nordisk in Danish high court

A press release from Novo Nordisk, comparing Novo's Tresiba to French Sanofi's insulins, was misleading, against the Medicines Act and a violation of good marketing practice. This is the judgment of the Danish Maritime and Commercial High Court.

Danish government in search for new notified body

As part of the growth plan for the life science industry, the Danish government will review the options for establishing a new notified body responsible for approving medical devices. The industry is delighted.

Growing deficit in Oncology Venture

Oncology Venture’s initiation of more drug developments has resulted in a growing deficit in the annual report 2017. However, the CEO is optimistic. Positive clinical data make for a promising future, he says.

Danish government wants to ease a door open for life science in Boston

A new office – or “innovation center” as the Danish government calls it – based in Boston, US, will give Danish companies access to researchers, projects and similar resources on the biggest US universities. This is according to the Danish Minister of Industry, Business and Financial Affairs.

"We have the potential to reinvent Lundbeck"

If Lundbeck succeeds in developing an Alzheimer's drug, it can potentially generate a revenue comparable to the whole company's current total revenue. This is according to EVP Bjørn Grønning.

New candidates in Zealand’s peptide pipeline

Danish biotech company Zealand Pharma’s pipeline contains several research projects including a phase I obesity candidate that, in the preclinical version, proved more effective than one of Novo’s drugs. Zealand is also turning to another Danish company’s preserves.

Japanese approval strategically important for ALK

Last week, Danish allergy group ALK obtained Japanese authorities’ approval for using a tablet vaccine, too. It fuels the company’s hope that the same approval can be achieved in other markets. However, the rival Stallergenes made the same move so the competition continues to be fierce.

Investor-aversion led to growth adventure for Gubra

Bad experiences made the founders of Gubra eager to keep investors out of the company. It slowed down the company’s development but at the same time, it made Gubra play a significant role in preclinical research and the Danish life science industry.

Science trio develops new candidate and aims for clinical trials

Innovation Fund Denmark has invested DKK 14 million in a new candidate against two eye diseases developed by three researchers from SDU. The candidate is to be ready for clinical trials in two years and according to one of the scientists, the work might result in a spinout.